Under construction – not a live service
Sign in
Taking people in SpainPhase 2

Long-term safety study of APG777 in people with atopic dermatitis

Tests APG777 over the long term in adults with atopic dermatitis, a skin condition.

Key facts

Who runs it
Apogee Therapeutics Inc.
Where
Alicante, Badalona, Las Palmas De Gran Canaria, Madrid, and Santiago de Compostela, SpainSee the 5 sitesAlso in 5 other countries, 35 sites
Registry title
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Status
Recruiting
Phase
Phase 2
People taking part
175 people, planned
Started
6 Oct 2025
Expected to end
1 Dec 2029
Type of study
Interventional
Record updated
18 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with atopic dermatitis who finished an earlier APG777 study and may benefit from continuing APG777 long term.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Atopic dermatitis (moderate-to-severe, as named in the trial summary).
Earlier treatment
Must have completed the treatment period of an earlier APG777 study and followed that study's plan. Must not have stopped that study early or permanently stopped the study drug.

Main reasons for not taking part

  • Stopped the earlier APG777 study early or permanently stopped the study drug
  • Had a side effect in the earlier study that may make more APG777 an unreasonable risk
  • Uses any prohibited medicine from the first screening visit of this study
  • Has other skin conditions or illnesses that could confuse the atopic dermatitis diagnosis or the study checks

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator’s opinion, compliant with the study protocol
  • Participants who, in the Investigator’s opinion, would benefit from long-term treatment with APG777
  • Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study

Who cannot take part

  • Participants who have developed an AE while participating in the Parent Study which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient
  • Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study
  • Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study
  • Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments

Where in Spain

Also in 5 other countries, 35 sites

  • Hospital General Universitario Dr. BalmisAlicante, SpainTaking people
  • Hospital Germans Trias i PujolBadalona, SpainTaking people
  • El Hospital Universitario De Gran Canaria Dr. NegrinLas Palmas De Gran Canaria, SpainTaking people
  • Icr Medical S.L.Madrid, SpainTaking people
  • Complexo Hospitalario Universitario De SantiagoSantiago de Compostela, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the long-term safety and tolerability of APG777 in patients with moderate-to-severe AD.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
APG777-202 - A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Plain-language title
Long-term safety study of APG777 in people with atopic dermatitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 August 2026